Sugi Predict

Sugi Predict / Compounds / SCHEMBL14949355

SCHEMBL14949355

SCHEMBL14949355

Cc1cccc(Nc2nnc(-c3cccc(Oc4ccnc5[nH]ccc45)c3)[nH]2)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 10/20 0.44
▸ TTBK1 Q5TCY1 1/20 0.43
▸ TTBK2 Q6IQ55 1/20 0.43
▸ KDR P35968 3/20 0.42
▸ BRAF P15056 1/20 0.40
▸ MAPK14 Q16539 1/20 0.40
▸ TNNI3K Q59H18 1/20 0.40
▸ ROCK2 O75116 3/20 0.38
▸ EGFR P00533 1/20 0.37
▸ ERBB2 P04626 1/20 0.37
▸ ERBB3 P21860 1/20 0.37
▸ ERBB4 Q15303 1/20 0.37
▸ CCNB2 O95067 1/20 0.37
▸ CDK1 P06493 1/20 0.37
▸ RET P07949 1/20 0.37
▸ CCNB1 P14635 1/20 0.37
▸ CCNB3 Q8WWL7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14949196 0.92 MET (0.49) METTTBK1TTBK2KDRBRAF
SCHEMBL12336529 0.86 BRAF (0.56) METTTBK1TTBK2KDRBRAF
SCHEMBL14949321 0.86 KDR (0.46) METKDRBRAFMAPK14TNNI3K
SCHEMBL14949372 0.86 KDR (0.42) METKDREGFRERBB2
SCHEMBL14949367 0.86 KDR (0.42) METKDREGFR
SCHEMBL14949314 0.85 TTBK1 (0.49) TTBK1TTBK2KDRBRAFMAPK14
SCHEMBL14949343 0.85 KDR (0.40) METKDRBRAFEGFRERBB2
SCHEMBL14949313 0.83 KDR (0.46) METKDRCCNB2CDK1CCNB1
SCHEMBL14949353 0.83 KDR (0.45) METKDREGFRCCNB2CDK1
SCHEMBL14949351 0.83 KDR (0.41) METKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2016-04-07 — — US disclosed
US-9212151-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-12-15 — — US disclosed
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2015-06-11 — — US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 — — US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 MET 770/4885TTBK1 221/4885TTBK2 185/4885
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 MET 770/4885TTBK1 221/4885TTBK2 185/4885
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 MET 770/4885TTBK1 221/4885TTBK2 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.